Inhibition of MiR-133 results in considerable cardiac hypertrophy and dysfunction, indicating its cardioprotective role in hypertrophic conditions by upregulating the targets Rho1, Cdc42, and Nelf-A/WHSC2. Here, NELFA is linked to cardiac hypertrophy.